Backdrop
Ceribell (NASDAQ: CBLL) priced its $207M initial public offering on October 10, 2024. The upsized, double-digit oversubscribed IPO priced above the initial pricing range and traded up ~47% on the first day of trading. Gilmartin Group served as Ceribell’s strategic IPO advisor and IR provider prior to and throughout its IPO process.
Issuer: Ceribell, Inc. (CBLL-US)
Offering Size (Gross): $207.3M
Initial Pricing Range: $14.00 – $16.00
Offer Price: $17.00
First Trade Day Closing Price: $25.00
Gilmartin Role, Support & Execution
Pre-IPO
- Investor targeting & relationship development
- Sell-side relationship management
- Conference/NDR management
- Presentation/pitch development
- Messaging & Q&A
- Press release drafting
- Peer benchmarking
- Valuation analysis
- BOD communications
- S-1 drafting
- IPO readiness assessment Banking syndicate advisory
IPO Execution
- Bake-off & Org meeting prep
- KPI strategy & TAM analysis
- Analyst diligence & model
- S-1 drafting
- TTW prep & targeting
- Exchange selection
- Roadshow presentation, script, Q&A
- Internal communications
- IR website build
- Allocation advisory
- Workflow/process management
Post-IPO Support
- Earnings materials development
- Guidance strategy
- Consensus model management
- Shareholder analysis & targeting
- Relationship management
- Marketing / IR calendar & logistics
- Investor conference/NDR support
- PR drafting and distribution
- Peer & industry surveillance / analysis
- Ongoing capital markets advisory
Transaction Significance & Results
Ceribell’s IPO marked the first growth MedTech IPO since October 2021. Gilmartin Group has served as a trusted advisor on ~70% of growth MedTech IPOs (min. $50M raise) over the last 6 years.
Our Clients
Our clients are leaders and innovators across the MedTech, Biotechnology, Digital Health, Life Science Tools & Diagnostic sectors
Gilmartin Blog
Gilmartin has a number of resources, from blog posts to webinars designed to educate and help your company achieve success.